Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK

Ru-Mei Chen, Yi‐Shiou Chiou, Qing-Yun Chong, Han-Ming Poh, Tuan Zea Tan, Meng-Yi Zhang, Lan Ma, Tao Zhu, Vijay Pandey, Basappa Basappa, Alan Prem Kumar, Peter E. LobieInternational Journal of Molecular Sciences 2019 · DOI

TL;DR

This study identifies Trefoil Factor 3 (TFF3) as a key driver of aggressive behavior in a particularly difficult-to-treat subtype of colorectal cancer (CMS4 CRC). They demonstrate that inhibiting TFF3 with a novel small molecule, AMPC, not only reduces cancer cell growth and spread but also re-sensitizes these cells to the chemotherapy drug 5-fluorouracil (5-FU), suggesting a promising new therapeutic strategy.

What Problem Does This Paper Address?

Colorectal cancer (CRC) is a major health concern, and while treatments exist, many patients develop resistance or their cancer progresses to a metastatic stage. A significant challenge is the heterogeneity of CRC, with different molecular subtypes exhibiting distinct clinical outcomes and responses to therapy. The mesenchymal subtype (CMS4) is particularly problematic, characterized by aggressive behavior, poor survival, and resistance to standard chemotherapy like 5-fluorouracil (5-FU). Currently, there's a lack of effective targeted therapies for this subtype. This paper addresses the need for better therapeutic strategies for CMS4 CRC by investigating the role of Trefoil Factor 3 (TFF3), a protein known to be upregulated in CRC and associated with metastasis, and exploring its inhibition as a potential treatment.

Methods

The researchers employed a multi-faceted approach to investigate TFF3's role and the efficacy of its inhibitor, AMPC. Key methods included:

  • Cell culture and manipulation: They used established CRC cell lines (Caco2 and SW620) and engineered them to either overexpress TFF3 (using a plasmid) or deplete TFF3 (using siRNA).
  • In vitro functional assays: A battery of tests were performed to assess cancer cell behavior, including:
  • Proliferation and survival: Measuring total cell numbers, cell cycle progression (using propidium iodide staining and flow cytometry), and apoptosis (using Annexin V/PI staining and Caspase-3/7 activity assays).
  • Motility and invasion: Transwell migration and invasion assays were used to quantify the ability of cells to move and penetrate barriers.
  • Cancer Stem Cell (CSC)-like properties: Assessed through spheroid formation assays and ALDH1 activity measurements, as CSCs are linked to chemoresistance and metastasis.
  • 3D Matrigel growth: To better mimic in vivo conditions, cells were cultured in a 3D matrix to evaluate colony formation and viability.
  • Pharmacological Inhibition: A novel small molecule inhibitor of TFF3, AMPC, was used to block TFF3's function. Its effects were evaluated across various assays.
  • Signaling Pathway Analysis: Western blotting was used to examine the activation of key signaling pathways, particularly the p44/42 MAPK (ERK1/2) pathway, which is implicated in cell survival and proliferation.
  • In vivo xenograft model: The therapeutic efficacy of AMPC was tested in mice bearing human SW620 tumors. Tumor growth, volume, weight, and histological features (necrosis, apoptosis, proliferation markers like Ki67) were analyzed.
  • Drug Combination Studies: The synergistic effects of AMPC and 5-FU were investigated using cell viability assays, foci formation, and 3D Matrigel growth, with statistical analysis (Chou-Talalay analysis) to determine synergy.

Datasets

The study utilized established human colorectal cancer cell lines: Caco2, SW620, and SW480. Data from The Cancer Genome Atlas (TCGA) was also analyzed to correlate TFF3 expression with patient survival outcomes in different CMS subtypes. No new datasets or benchmarks were introduced.

Key Insights and Ideas

  • TFF3 as a driver of CMS4 CRC aggressiveness: The research strongly implicates TFF3 as a key factor promoting the aggressive characteristics of CMS4 CRC cells, including increased proliferation, survival, migration, invasion, and CSC-like behavior. This is a crucial finding for understanding why CMS4 is so difficult to treat.
  • TFF3 activates the ERK1/2 pathway: The study provides evidence that TFF3 exerts its pro-oncogenic effects, at least in part, by activating the p44/42 MAPK (ERK1/2) signaling pathway, which is known to be involved in cell survival and proliferation.
  • AMPC effectively inhibits TFF3 and its downstream effects: The novel small molecule inhibitor AMPC demonstrated potent inhibition of TFF3, leading to a reduction in the oncogenic behaviors observed in CMS4 CRC cells, both in vitro and in vivo. This validates AMPC as a promising therapeutic agent.
  • TFF3 confers 5-FU resistance: A critical insight is that elevated TFF3 expression directly contributes to resistance to 5-FU chemotherapy. Conversely, depleting TFF3 enhances sensitivity to 5-FU. This explains a part of the therapeutic challenge in CMS4 CRC.
  • Synergistic effect of AMPC and 5-FU: The combination of AMPC and 5-FU showed a synergistic inhibitory effect on CMS4 CRC cells, meaning their combined effect was greater than the sum of their individual effects. This is a highly significant finding for developing combination therapies.

Key Results

  • Forced TFF3 expression in Caco2 cells significantly increased cell proliferation, survival, migration, invasion, and CSC-like properties.
  • TFF3 depletion in SW620 cells reversed these effects, decreasing proliferation, survival, and CSC-like behavior.
  • AMPC treatment significantly inhibited tumor growth in a mouse xenograft model, reducing tumor volume and weight, and increasing necrosis and apoptosis.
  • TFF3 activation of ERK1/2 was demonstrated through Western blot analysis, showing increased p-ERK1/2 levels with TFF3 overexpression and decreased levels with TFF3 depletion.
  • 5-FU resistance was directly linked to TFF3 expression: Caco2 cells with forced TFF3 expression showed a ~6-fold increase in 5-FU IC50 values, while TFF3-depleted SW620 cells showed a decrease.
  • AMPC and 5-FU combination therapy demonstrated synergistic inhibitory effects in SW620 and Caco2 cells, with combination index (CI) values consistently below 1. This also allowed for a significant dose reduction of 5-FU.

Limitations and Future Work

  • In vitro to in vivo translation: While the study shows promising results in vitro and in a xenograft model, further validation in more complex preclinical models and ultimately in human clinical trials is necessary.
  • Specificity of AMPC: While the study suggests AMPC's specificity for TFF3, further detailed mechanistic studies on off-target effects might be beneficial.
  • Biomarker potential: The study suggests serum TFF3 could be a response marker for AMPC treatment, which warrants further investigation for clinical utility.
  • Broader CMS4 context: While focused on CMS4, exploring the role of TFF3 in other CRC subtypes or other cancers where TFF3 is implicated could broaden its therapeutic relevance.
  • Combination therapy optimization: Further studies could focus on optimizing the dosing and scheduling of AMPC and 5-FU for maximum therapeutic benefit and minimal toxicity in clinical settings.

Summary updated

Abstract

Increased expression of trefoil factor 3 (TFF3) has been reported in colorectal carcinoma (CRC), being correlated with distant metastasis and poor clinical outcomes. Amongst the CRC subtypes, mesenchymal (CMS4) CRC is associated with the worst survival outcome. Herein, the functional roles of TFF3 and the pharmacological inhibition of TFF3 by a novel specific small molecule TFF3 inhibitor-2-amino-4-(4-(6-fluoro-5-methylpyridin-3-yl)phenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carbonitrile (AMPC) in CMS4 CRC was explored. Forced expression of TFF3 in CMS4 CRC cells promoted cell proliferation, cell survival, foci formation, invasion, migration, cancer stem cell like behaviour and growth in 3D Matrigel. In contrast, siRNA-mediated depletion of TFF3 or AMPC inhibition of TFF3 in CMS4 CRC cells decreased oncogenic behaviour as indicated by the above cell function assays. AMPC also inhibited tumour growth in vivo. The TFF3-stimulated oncogenic behaviour of CMS4 CRC cells was dependent on TFF3 activation of the p44/42 MAPK (ERK1/2) pathway. Furthermore, the forced expression of TFF3 decreased the sensitivity of CMS4 CRC cells to 5-fluorouracil (5-FU); while depleted TFF3 expression enhanced 5-FU sensitivity in CMS4 CRC cells. 5-FU treatment induced TFF3 expression in CMS4 CRC cells. AMPC, when used in combination with 5-FU in CMS4 CRC cells exhibited a synergistic inhibitory effect. In summary, this study provides functional evidence for TFF3 as a therapeutic target in CMS4 CRC.
BibTeX
@article{chen2019pharmacological,
  author = {Ru-Mei Chen and Yi‐Shiou Chiou and Qing-Yun Chong and Han-Ming Poh and Tuan Zea Tan and Meng-Yi Zhang and Lan Ma and Tao Zhu and Vijay Pandey and Basappa Basappa and Alan Prem Kumar and Peter E. Lobie},
  title = {{Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK}},
  journal = {International Journal of Molecular Sciences},
  year = {2019},
  doi = {10.3390/ijms20246215},
}
Figure